(Q35779329)

10 August 2017

1 reference

title

Psychotic symptoms in Parkinson's disease: pathophysiology and management (English)

1 reference

10 August 2017

1 reference

1 reference

Bosboom JL

1

1 reference

10 August 2017

Wolters ECh

series ordinal

2

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

Expert Opinion on Drug Safety

10 August 2017

published in

1 reference

10 August 2017

volume

3

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

209-220

1 reference

Risk factors for nursing home placement in advanced Parkinson's disease.

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Hallucinosis in idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Prospective longitudinal assessment of hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Mental dysfunction in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Visual hallucinations associated with Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Early dopaminergic drug-induced hallucinations in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Confusion, dementia and anticholinergics in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Parkinson's disease and dementia with Lewy bodies: one disease or two?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Cognitive profiles of autopsy-confirmed Lewy body variant vs pure Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Prospective study of hallucinations and delusions in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

A study of visual hallucinations in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Auditory hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Visual hallucinations in Parkinson's disease: a review and phenomenological survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Delusions and hallucinations in Alzheimer's disease: review of the brain decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Parallel Organization of Functionally Segregated Circuits Linking Basal Ganglia and Cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

The neuropathologic basis of different clinical subgroups of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Dopamine deficiency in the cerebral cortex in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Is the mesocortical dopaminergic system involved in Parkinson disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Dopamine and the regulation of cognition and attention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Dopaminergic modulation of cortical function in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Selective loss of central cholinergic neurons in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Basal forebrain neurons in the dementia of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Cholinergic correlates of cognitive impairment in Parkinson's disease: comparisons with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Cholinergic dysfunction in diseases with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Topography, Extent, and Clinical Relevance of Neurochemical Deficits in Dementia of Lewy Body Type, Parkinson's Disease, and Alzheimer's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Convergent cholinergic activities in aging and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Central cholinergic systems and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

The pedunculopontine nucleus in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Clinical and quantitative pathologic correlates of dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Levodopa-induced psychosis: a kindling phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Serotonin Reuptake Inhibitors, Paranoia, and the Ventral Basal Ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Serotonin receptors: their key role in drugs to treat schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Neuroleptic sensitivity in patients with senile dementia of Lewy body type

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Dopamine D2 receptors in demented patients with severe neuroleptic sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Olanzapine usage associated with neuroleptic malignant syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Clozapine in Parkinson's disease psychosis: 5-year follow-up review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Seroquel: biochemical profile of a potential atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Efficacy of quetiapine in Parkinson's patients with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Long‐term outcome of quetiapine use for psychosis among parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Worsening of motor features of parkinsonism with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Olanzapine treatment for dopaminergic-induced hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Risperidone treatment of drug-related psychosis in patients with parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Neuroleptic sensitivity to risperidone in Lewy body dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Dementia with Lewy bodies: response of delirium-like features to donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.3.3.209

21 January 2018

Identifiers

DOI

10.1517/14740338.3.3.209

1 reference

10 August 2017

1 reference